Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of AMG 133 in Overweight or Obesity
NCT07717814Phase 1Completed
- Sponsor
- Amgen
- Start
- Nov 2024
- Primary completion
- May 2025
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of maridebart cafraglutide in obesity (3 arms), sponsored by Amgen. Primary endpoints: Maximum Observed Concentration, Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration and 1 more. Started Nov 2024; status: completed.
02
Drugs
maridebart cafraglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07717814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07717814.